10
Participants
Start Date
August 31, 2009
Primary Completion Date
May 31, 2010
Study Completion Date
February 28, 2011
Mesenchymal Precursor cells (RevascorTM)
Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
Cryoprotective media alone
Participants will receive intramyocardial injections of cryoprotective media (placebo).
Mount Sinai Medical Center, New York
Columbia University Medical Center, New York
Montefiore Medical Center, The Bronx
Hospital of the University of Pennsylvania, Philadelphia
Temple University Hospital, Philadelphia
Washington Hospital Center, Washington D.C.
Jewish Hospital, Louisville
Ohio State University Medical Center, Columbus
University of Michigan, Ann Arbor
St. Luke's Medical Center, Milwaukee
University of Wisconsin, Madison
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Advocate Christ Medical Center, Oak Lawn
Intermountain Medical Center, Salt Lake City
Sharp Memorial Hospital, San Diego
Sacred Heart Medical Center, Spokane
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Angioblast Systems
INDUSTRY
Icahn School of Medicine at Mount Sinai
OTHER